Ann Thorac Surg 2002;74:1166
© 2002 The Society of Thoracic Surgeons
Invited commentary
Subodh Verma, MD, PhDa,
Richard D. Weisel, MDa,
Ren-Ke Li, Dra
a Division of Cardiac Surgery, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON, Canada M5G 2C4
| The first 20% of the full text of this article appears below. |
Vein graft atherosclerosis remains a formidable problem limiting long-term effectiveness of conventional coronary artery bypass graft surgery (CABG). Developing simple and efficient strategies to effectively counter the mechanisms and mediators of vein graft atherosclerosis is an area of intense investigation. Vein graft atherosclerosis can be targeted through a number of approaches, both systemically and locally. The systemic use of drugs that modify endothelial function, attenuate platelet-endothelial cell interaction, and counter smooth muscle proliferation are routinely employed following CABG surgery; yet the patency rates of saphenous veins remain an imminent problem. This has led to a renewed . . . [Full Text of this Article]
Copyright © 2002 by The Society of Thoracic Surgeons.